April 25, 2023
As we’ve communicated to the CRD and scientific communities, a team of researchers and clinicians led by Yale University and UMass Chan Medical School has been studying what happened to Terry. We wanted to provide an update that their study will be published on the pre-print server medRxiv.org within the next three weeks.
Our focus has been on getting the best learnings we can from Terry’s outcome and sharing those learnings for the benefit of the entire scientific community, and we thank you for your patience during this important process.
Our research and development is powered by the generous financial support of families, rare disease communities and organizations unwilling to accept the status quo of drug development practices. As a 501c3 non-profit biotech, 93+% of all donations go directly to the research and development of life-saving therapies.
We offer a number of ways to get involved with moving science forward. Learn More